Aghajanian C et al. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gyn Oncol 2021;162(2):375-81. Abstract
Alvarez Secord A et al. PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FR-alpha) expression. SGO 2022;Abstract 300.
Arend RC et al. Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel vs paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). ASCO 2021;Abstract TPS5599.
Banerjee et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(12):1721-31. Abstract
Campbell R et al. Measure of ovarian symptoms and treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecol Oncol 2022;166(2):254-62. Abstract
Clam AR et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): Overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2022;23(7):919-30. Abstract
Colombo N et al. Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer. ASCO 2022;Abstract LBA5503.
Drew Y et al. Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in the germline BRCA-mutated platinum-sensitive relapsed ovarian cancer cohort. ESMO 2019;Abstract 1190PD.
Drew Y et al. Phase II study of olaparib plus durvalumab and bevacizumab (MEDIOLA): Initial results in patients with non-germline BRCA-mutated platinum sensitive relapsed ovarian cancer. ESMO 2020;Abstract 814MO.
Elyashiv O et al. Frontline maintenance treatment for ovarian cancer. Curr Oncol Rep 2021;23(8):97. Abstract
Flynn MJ, Ledermann JA. Ovarian cancer recurrence: Is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer. Cancer Drug Resist 2022;5(2):424-35. Abstract
Gonzalez-Martin A et al. Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials. ASCO 2021;Abstract 5518.
Hardesty MM et al. Phase 2 OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following frontline platinum-based chemotherapy with bevacizumab. SGO 2022;Abstract 40.
Hurvitz SA. DESTINY-changing results for advanced breast cancer. N Engl J Med 2022;387(1):75-6. Abstract
Jacot W et al. Trastuzumab deruxtecan (T-DXd) vs treatment with physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.
Konstantinopoulos PA et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;5(8):1141-9. Abstract
Kristeleit R et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and deleterious BRCA1 or BRCA2 mutation (ARIEL4): An international, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(4):465-78. Abstract
Kwan TT et al. Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib. JAMA Oncol 2021;7(12):1772-81. Abstract
Leary A et al. Immune checkpoint inhibitors in ovarian cancer: Where do we stand? Ther Adv Med Oncol 2021;13:17588359211039899. Abstract
Ledermann JA. Testing for homologous recombination deficiency – Does it provide new insights for the use of veliparib? Gynecol Oncol 2022;164(2):243-44. Abstract
Lee CK et al. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer 2021;127(14):2432-41. Abstract
Lee YC et al. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: The Gynecologic Cancer InterGroup-Symptom Benefit study. Int J Gynecol Cancer 2022;32(6):761-8. Abstract
Li N et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): A randomized, double-blind, placebo-controlled, phase 3 trial. SGO 2022;Abstract LBA5.
Liu JF et al. An open-label phase 2 study of dostarlimab, bevacizumab, and niraparib combination in patients with platinum-resistant ovarian cancer: Cohort A of the OPAL trial. SGO 2021;Abstract 10415.
Liu N. Highlights of the gynecologic cancers track. ASCO 2022;Abstract.
Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. SGO 2022;Abstract LBA4.
Matulonis UA et al. Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR-alpha) expression: Characterization of antitumor activity in the SORAYA study. ASCO 2022;Abstract 5512.
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract
Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;[Online ahead of print]. Abstract
Monk BJ et al. ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer 2021;31(12):1589-94. Abstract
Monk BJ et al. ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. ASCO 2022;Abstract LBA5500.
Moore KN et al. MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal or fallopian tube cancers with high folate receptor alpha (FRa) expression. SGO 2022;Abstract 297.
O’Malley DM et al. Mirvetuximab soravtansine, a folate receptor alpha (FR-alpha)-targeting antibody drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. ASCO 2021;Abstract 5504.
Poveda A. Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis. ASCO 2022;Abstract 5545.
Pujade-Lauraine E et al. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial. ESMO 2022;Abstract LBA33.
Randall LM et al. MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). ASCO 2022;Abstract 5573.
Richardson DL et al. Updated results from the phase 1b expansion study of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in ovarian cancer. SGO 2022;Abstract 76.
Selle F et al. OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts. ASCO 2022;Abstract 5558.
Swisher EM et al. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the phase 3 VELIA/GOG-3005 study. Gynecol Oncol 2022;164(2):245-53. Abstract
Tjokrowidjaja A et al. Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance Olaparib therapy following response to chemotherapy. Eur J Cancer 2021;154:190-200. Abstract
Wood GE, Ledermann JA. Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. Best Pract Resea Clin Obst Gyn 2022;78:64-73. Abstract